Results 151 to 160 of about 2,882 (191)

Olmesartan-associated gastroduodenitis that was detected on endoscopic follow-up. [PDF]

Clin J Gastroenterol
Oki Y, Yamada T, Tatsuno M, Iguchi M, Miyachi H, Uchida K.   +5 more
europepmc   +1 more source

Effectiveness of single-pill combination olmesartan/amlodipine/hydrochlorothiazide therapy in patients with apparent resistant hypertension. [PDF]

J Hum Hypertens
Oh J, Kim W, Kim GH, Kim HL, Park SD, Min KW, Hyun D, Hong JH, Lim S, Bae JH, Shin J, RESOLVE-INT Investigators.   +11 more
europepmc   +1 more source

Safety of combination therapy of azilsartan medoxomil and amlodipine: a population-based cohort study. [PDF]

Epidemiol Health
Lee H, Hong B, Su CT, Bea S, Jeong HE, Jung K, Cheng MC, Chang ZC, Lai EC, Lee J.   +9 more
europepmc   +1 more source

Enhancing Oral Absorption of an Ester Prodrug by Coating Drug Crystals with Binary Lipid Systems and Evaluating the Influence of Compositions. [PDF]

Pharmaceutics
Dong X, Zhang T, Moreno Sanchez HL, Mans JC, Bae SH, Bian L.   +5 more
europepmc   +1 more source

Activity of GPCR-targeted drugs influenced by human gut microbiota metabolism. [PDF]

Nat Chem
Wu Q, Song D, Zhao Y, Verdegaal AA, Turocy T, Duncan-Lowey B, Goodman AL, Palm NW, Crawford JM.   +8 more
europepmc   +1 more source

Biofunctional Pharmaceutical Additives for Targeted, Improved Bioavailability and Safety of Medicine. [PDF]

Pharmaceutics
Abdelkader H, Fatease AA, Wu Z.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Olmesartan Medoxomil

Drugs, 2002
Olmesartan medoxomil is a nonpeptide angiotensin II receptor antagonist which selectively and competitively inhibits the type 1 angiotensin II receptor without affecting other receptors regulating the cardiovascular system. In well designed randomised trials, olmesartan medoxomil was significantly more effective than placebo, and at dosages of 10 to 20
Gregory T, Warner, Blair, Jarvis
openaire   +2 more sources

Olmesartan Medoxomil/Amlodipine

Drugs, 2009
black triangle Olmesartan medoxomil/amlodipine is a fixed-dose combination of olmesartan medoxomil and amlodipine, both established antihypertensive agents. Dose titration with the individual constituent drugs is recommended before switching to the equivalent fixed-dose combination.
Mark, Sanford, Susan J, Keam
openaire   +2 more sources

Olmesartan medoxomil

Reactions Weekly, 2019
  +10 more sources

Olmesartan Medoxomil

Drugs, 2012
exaly   +2 more sources